Conclusions
dose-limiting, neuropathy
PERIPHERAL NEUROPATHY, ADVERSE EFFECT, NEUROPATHY
Paclitaxel is among the most commonly prescribed chemotherapeutic agents and has neuropathy as a common dose-limiting adverse effect. We have no phase 3 evidence-based measures to prevent the incidence of severe paclitaxel-induced neuropathy. One phase 2 trial has demonstrated the potential role of oral gabapentin for the same. This study is a randomized phase III, placebo-controlled, double-blind, parallel-group, superiority trial designed to assess the efficacy of oral gabapentin in preventing paclitaxel-induced peripheral neuropathy.